BioMarin Pharmaceutical Inc.

Researches and develops therapies for debilitating, fatal, chronic genetic disorders causing enzyme deficiency of carbohydrate metabolism, such as phenylketonuria. Headquarters in Novato, California. (Nasdaq: BMRN).